Apyx Medical (NASDAQ:APYX) Upgraded at Zacks Research

Zacks Research upgraded shares of Apyx Medical (NASDAQ:APYX) to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

A number of other research analysts also recently commented on APYX. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Apyx Medical in a research report on Wednesday, October 8th. Roth Capital initiated coverage on Apyx Medical in a report on Monday. They issued a “buy” rating and a $6.00 target price for the company. Finally, Citizens Jmp raised Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Apyx Medical Trading Down 5.9%

Apyx Medical stock opened at $3.49 on Wednesday. Apyx Medical has a 12-month low of $0.76 and a 12-month high of $4.44. The firm has a market capitalization of $133.46 million, a price-to-earnings ratio of -9.69 and a beta of 1.49. The firm has a 50 day moving average of $3.63 and a 200 day moving average of $2.64. The company has a current ratio of 4.44, a quick ratio of 3.61 and a debt-to-equity ratio of 5.69.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The business had revenue of $12.88 million during the quarter, compared to analyst estimates of $12.00 million. Apyx Medical had a negative net margin of 30.35% and a negative return on equity of 151.01%. As a group, research analysts predict that Apyx Medical will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in Apyx Medical during the 3rd quarter valued at about $28,000. Fisher Asset Management LLC bought a new stake in shares of Apyx Medical during the second quarter valued at approximately $34,000. Caprock Group LLC bought a new stake in shares of Apyx Medical during the third quarter valued at approximately $40,000. Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical in the second quarter valued at approximately $50,000. Finally, Franklin Resources Inc. bought a new position in Apyx Medical in the third quarter worth approximately $59,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.